Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Platinum-Resistant Ovarian Carcinoma Clear all
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
Interventions
TRX518, Cyclophosphamide, Avelumab
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced May 22, 2026, 12:05 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Interventions
OPB-101
Biological
Lead sponsor
Outpace Bio, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Detroit, Michigan • Minneapolis, Minnesota • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Laboratory Biomarker Analysis, Poly ICLC
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Duarte, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
SGI-110, Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine), Carboplatin
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
celecoxib, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Topotecan Hydrochloride
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer
Interventions
mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Topotecan, Bevacizumab
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Batiraxcept, Durvalumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced May 22, 2026, 12:05 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Nivolumab, Etigilimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Ixabepilone, Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
PEG-interferon alfa-2b, PEG-interferon alfa-2b
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced May 22, 2026, 12:05 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
capecitabine, docetaxel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, Paclitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced May 22, 2026, 12:05 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
8
States / cities
Duarte, California • South Pasadena, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
pemetrexed disodium
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Hinsdale, Illinois • Urbana, Illinois • Boston, Massachusetts + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Vallejo, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced May 22, 2026, 12:05 AM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced May 22, 2026, 12:05 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Recurrent Platinum Resistant Ovarian Cancer
Interventions
VB-111 + Paclitaxel, Placebo + Paclitaxel
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
64
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced May 22, 2026, 12:05 AM EDT